闽西南地区炎症性肠病诊治特征的研究

doi:10.3969/j.issn.1000-8535.2022.06.019

广州医药 ›› 2022, Vol. 53 ›› Issue (6): 89-95.DOI: 10.3969/j.issn.1000-8535.2022.06.019

闽西南地区炎症性肠病诊治特征的研究

林逊汀¹, 赖小鑫², 林媛¹, 施华秀¹

1 厦门大学附属中山医院消化内科(厦门 361000)
2 厦门市海沧医院消化内科(厦门 361000)

收稿日期:2022-05-25 出版日期:2022-11-20 发布日期:2022-11-30
通讯作者: 施华秀,E-mail: huaxiushi@xmu.edu.cn

Diagnostic and treatment features of regional inflammatory bowel disease

LIN Xunting¹, LAI Xiaoxin², LIN Yuan¹, SHI Huaxiu¹

1 Department of Gastroenterology, Zhongshan Hospital, Xiamen University,Xiamen 361000,China
2 Department of Gastroenterology,Xiamen Haicang Hospital,Xiamen 361000,China

Received:2022-05-25 Online:2022-11-20 Published:2022-11-30

摘要/Abstract

摘要： 目的分析闽西南地区在院炎症性肠病患者流行病学资料,从而加强对炎症性肠病的认识。方法回顾性研究炎症性肠病患者临床特点及用药情况。结果纳入317例炎症性肠病,克罗恩病占212例,男女之比 2.07:1,溃疡性结肠炎占105例,男女比例1.84:1。克罗恩病患者确诊平均年龄29岁,以患A2型为主,溃疡性结肠炎者确诊平均年龄44岁。女性B2型比例明显高于男性。溃疡性结肠炎患者的病变部位主要为E3型(44.8%)。结论炎症性肠病患者临床表现多样。克罗恩病确诊年龄主要是A2型, L3型是主要病变部位分型,B2型是疾病行为主要分型。E3型是溃疡性结肠炎患者的主要病变部位。克罗恩病多以免疫抑制剂和生物制剂治疗,糖皮质激素和5-ASA类制剂是轻中度的UC患者主要治疗措施。生物制剂、糖皮质激素治疗多用于重度UC患者。

关键词: 克罗恩病, 溃疡性结肠炎, 炎症性肠病

Abstract: Objective To analyze the epidemiological data of inflammatory bowel disease (IBD)patients in southwest Fujian Province, so as to improve the understanding of IBD. Methods To retrospectively study the clinical characteristics and medication of inflammatory bowel disease patients. Results A total of 317 IBD patients were included.Crohn's disease accounted for 212 cases, with a male-to-female ratio of 2.07:1, and ulcerative colitis accounted for 105 cases, with a male-to-female ratio of 1.84:1.Patients with Crohn's disease were diagnosed at an average age of 29, mainly with type A2, while patients with ulcerative colitis were diagnosed at an average age of 44. The proportion of female with type B2 was significantly higher than that of male.The lesions of ulcerative colitis patients were mainly type E3 (44.8%).Conclusions Patients with IBD had diverse clinical manifestations.The age of diagnosis of Crohn's disease was mainly type A2, type L3 was the main lesion, type B2 was the main disease classification.Crohn's disease was mainly treated with immunosuppressive and biological therapy. Glucocorticoids and 5-ASA were the main treatment for patients with mild-to-moderate ulcerative colitis. Biological agents and glucocorticoid therapy were mostly used in severe patients.

Key words: Crohn's disease, ulcerative colitis, inflammatory bowel disease

林逊汀, 赖小鑫, 林媛, 施华秀. 闽西南地区炎症性肠病诊治特征的研究[J]. 广州医药, 2022, 53(6): 89-95.

LIN Xunting, LAI Xiaoxin, LIN Yuan, SHI Huaxiu. Diagnostic and treatment features of regional inflammatory bowel disease[J]. Guangzhou Medical Journal, 2022, 53(6): 89-95.

参考文献

[1] ANANTHAKRISHNAN A N. Epidemiology and risk factors for IBD[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(4): 205-217.
[2] 吴开春,梁洁,钱家鸣,等. 炎症性肠病诊断与治疗的共识意见(2018年,北京)[J]. 中华消化杂志, 2018,38(5): 292-311.
[3] NG S C, KAPLAN G G, TANG W, et al. Population density and risk of inflammatory bowel disease: A prospective population-based study in 13 countries or regions in Asia-Pacific[J]. Am J Gastroenterol, 2019,114(1): 107-115.
[4] SOON I S, MOLODECKY N A, RABI D M,et al. The relationship between urban environment and the inflammatory bowel diseases: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2012(12): 51.
[5] LI X, SONG P, LI J, et al. The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: A systematic review and Meta-analysis[J]. Int J Environ Res Public Health, 2017, 14(3):238.
[6] FREEMAN H J. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients[J]. Can J Gastroenterol, 2007, 21(6): 363-366.
[7] ZHAO J, NG S C, LEI Y,et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of “western” disease[J]. Inflamm Bowel Dis, 2013,19(9):1839-1845.
[8] 杨荣萍, 高翔,何瑶等.中国南方地区克罗恩病蒙特利尔分型特征分析[J]. 胃肠病学和肝病学杂志, 2014,23(1): 70-74.
[9] GUPTA N, BOSTROM A G, KIRSCHNER B S,et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease[J]. Pediatrics, 2007, 120(6): 1418-1425.
[10] INGLE S B, LOFTUS E V Jr. The natural history of perianal Crohn's disease[J]. Dig Liver Dis, 2007, 39(10): 963-969.
[11] ROWAN C R, CULLEN G, MULCAHY H E,et al. DUBLIN [Degree of Ulcerative Colitis Burden of Luminal Inflammation] score, a simple method to quantify inflammatory burden in ulcerative colitis[J]. J Crohns Colitis, 2019, 13(11): 1365-1371.
[12] CHEN L, YANG J, FANG L, et al. The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium-to long-term prognosis in patients with active ulcerative colitis[J]. Therap Adv Gastroenterol, 2020(13): 1756284820981210.
[13] PEYRIN-BIROULET L, BOUHNIK Y, ROBLIN X, et al. French national consensus clinical guidelines for the management of ulcerative colitis[J]. Dig Liver Dis, 2016, 48(7): 726-733.
[14] SIMIAN D, FLUXÁ D, FLORES L,et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients[J]. World J Gastroenterol, 2016, 22(22): 5267-5275.
[15] PRIDEAUX L, KAMM M A, de CRUZ P, et al. Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne[J]. JGastroenterol Hepatol, 2012, 27(5): 919-927.
[16] PARK S J, KIM W H, CHEON J H. Clinical characteristics and treatment of inflammatory bowel disease:a comparison of Eastern and Western perspectives[J]. World J Gastroenterol, 2014,20(33): 11525-11537.

闽西南地区炎症性肠病诊治特征的研究

Diagnostic and treatment features of regional inflammatory bowel disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	李永强, 首第文, 徐豪明, 黄红丽, 陈慧婷, 唐文娟, 李瑜元, 周永健. 标准化粪菌移植技术的临床应用[J]. 广州医药, 2021, 52(3): 117-122.
[2]	谌黄威, 刘浏, 熊婷, 罗夏朋, 黄鹤, 贾柳萍. 炎症性肠病活动程度与血脂水平的相关性分析[J]. 广州医药, 2019, 50(2): 24-27.
[3]	潘丹峰, 苍玉珍. 应用膳食平衡指数评价溃疡性结肠炎患者膳食质量及营养状况[J]. 广州医药, 2018, 49(4): 34-38.
[4]	沈峰, 王博文. 水解乳清蛋白对炎症性肠病大鼠的抗炎作用及机制研究[J]. 广州医药, 2015, 46(6): 18-19.